This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction, and digestive enzyme disorders.
For each major segment, the analysis provides an overview of the diseases including epidemiology, a detailed description of products on the market, products in research and development, and market estimates and forecasts through 2010 by drug type and by geographical market (U.S. and non-U.S). Competitive market share information is also provided for 2005 and projected for 2010now and and top drugs. The analysis includes market projections for:
- H2 receptorantagonists,
- proton pump inhibitors (PPIs),
- other antacid/antiulcer therapeutics,
- immunotherapy for GI cancers,
- chemotherapy for GI cancers,
- enzymes, and
- several other miscellaneous GI drug categories
In addition to market data, the report includes current issues and trends affecting the industry and what trends may arise in the future and profiles the top competitors in the field.
The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information—specifically revenue and market share data—presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.